Pyrogen Testing Methods

Pyrogen testing defines a process used by drug manufacturers to determine if bacterial toxins are present in vaccines and drugs that might cause fever when used on humans. It determines if microbes or their metabolites are present in intravenous solutions during the manufacturing process. The most common and oldest form of pyrogen testing consists of injecting drugs into rabbits to determine if a fever develops. A newer test uses blood from the horseshoe crab to test for toxins.

Pyrogen test is performed to check the presence or absence of pyrogens in all aqueous parenterals. Rabbits are used to perform the test because their body temperature increases when pyrogen is introduced by parenteral route.

Pyrogen Testing Procedure

The sensitivity is 1pg/ml, the test result is close to the real condition of the human body, and the operation is tedious and time-consuming

Rabbits for trial: 1.7~3.0 kg. The body temperature is 38~39.6℃, and the difference between the highest and lowest body temperature is no more than 0.4℃. It can be used after resting for 48 hours.
Experimental preparation: The room temperature is 17~25℃, and the temperature change should not exceed 3℃.
Inspection: 3 pieces. The medicine solution warmed to 38℃ is injected into the ear vein. It is measured every 30 minutes, 6 times. The normal body temperature is subtracted from the highest one of the 6 body temperatures, which is the temperature at which the rabbit’s body temperature rises.
Judgment: The body temperature rise of 3 animals is lower than 0.6℃, and the total body temperature rise of 3 animals is lower than 1.4℃.

For this test three healthy rabbits are selected each weighing at least 1.5 kg. No rabbit should be selected if:

1. It has normal temperature greater than 49.8°C.

2. It was used in positive test during last two weeks or negative test during last two days.

Pyrogen in Parenterals Method for Pyrogen Test:

The pyrogen testing is performed in an air conditioned room. The food and water is withheld to rabbit overnight. Clinical thermometer is inserted in the rectum of each rabbit to a depth of not less than 7.5 cm. Two readings of temperature of rabbit in normal conditions should be taken at the interval of half an hour before start the test and mean of the both should be calculated to determine the initial temperature.

The equipments, injectors and needles used in the test should be pyrogen free. These should be washed with water for injection and then heated at 260°C for two hours. The injection is warmed to 38°C before inject to the rabbits. 0.5 to 1.0 ml per kg dose should be injected through the ear vein. Six reading of temperature are recorded at an interval of half an hour.

Pyrogen Test Results:

The response of each rabbit is detected by difference of initial temperature and the highest temperature recorded. The response of all three rabbits gives the sum of responses and can be concluded as:

i) If the sum of responses dose not greater than 1.4°C and any of rabbit shows the response less than 0.6° C, the product passes the test.
ii) I sum of responses is greater than 1.4 °C or any of rabbit shows the response 0.6 or greater, continue the test using 5 rabbits.
iii)If test is done using 5 rabbits, than if sum of responses of all 5 rabbits is greater than 3.7°C and the individual response of not more than three rabbits is greater than 0.6°C, the product passes the test.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客